Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Raised to Hold at Barclays

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) was upgraded by equities research analysts at Barclays from a “strong sell” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Separately, Kepler Capital Markets raised Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Price Performance

Recordati Industria Chimica E Farmaceutica stock opened at $65.44 on Thursday. Recordati Industria Chimica E Farmaceutica has a 1 year low of $49.00 and a 1 year high of $65.44. The firm’s 50-day moving average is $65.44 and its 200-day moving average is $65.44. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.16 and a current ratio of 1.64.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.